Head-To-Head Survey: Helius Medical Technologies (NASDAQ:HSDT) and Heyu Biological Technology (OTCMKTS:HYBT)

Helius Medical Technologies (NASDAQ:HSDT) and Heyu Biological Technology (OTCMKTS:HYBT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Helius Medical Technologies and Heyu Biological Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Helius Medical Technologies	-1,328.14%	-297.49%	-107.36%
Heyu Biological Technology	-453.55%	-6.43%	-4.43%

Volatility & Risk

Helius Medical Technologies has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Heyu Biological Technology has a beta of -17.74, meaning that its stock price is 1,874% less volatile than the S&P 500.

Institutional & Insider Ownership

18.6% of Helius Medical Technologies shares are owned by institutional investors. 5.1% of Helius Medical Technologies shares are owned by insiders. Comparatively, 89.2% of Heyu Biological Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Helius Medical Technologies and Heyu Biological Technology’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helius Medical Technologies	$594,000.00	3.99	-$8.85 million	($13.04)	-0.06
Heyu Biological Technology	$80,000.00	322.65	-$270,000.00	N/A	N/A

Heyu Biological Technology has lower revenue, but higher earnings than Helius Medical Technologies.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Helius Medical Technologies and Heyu Biological Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helius Medical Technologies	0	0	1	0	3.00
Heyu Biological Technology	0	0	0	0	N/A

Helius Medical Technologies presently has a consensus price target of $24.00, indicating a potential upside of 2,899.63%. Given Helius Medical Technologies’ higher possible upside, research analysts plainly believe Helius Medical Technologies is more favorable than Heyu Biological Technology.

Summary

Heyu Biological Technology beats Helius Medical Technologies on 6 of the 11 factors compared between the two stocks.

About Helius Medical Technologies

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About Heyu Biological Technology

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.